Litigation Details for Apotex Inc. v. Daiichi Sankyo, Inc. (Fed. Cir. 2016)
✉ Email this page to a colleague
Apotex Inc. v. Daiichi Sankyo, Inc. (Fed. Cir. 2016)
| Docket | ⤷ Try a Trial | Date Filed | 2016-05-16 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | 2016-10-24 |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 6,878,703 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Apotex Inc. v. Daiichi Sankyo, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Apotex Inc. v. Daiichi Sankyo, Inc. (Fed. Cir. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-05-16 | 7 | Benicar HCT. Id. U.S. Patent No. 6,878,703 (“the ’703 patent”) is the sole patent at issue in both cases…United States Patents Nos. 6,878,703 (the “‘703 Patent”) and 5,616,599 (the “‘599 Patent”) in connection…United States Patents Nos. 6,878,703 (the “703 patent”) and 5,616,599 (the “599 patent”) with the FDA…not infringe any claims of U.S. Patent No. 6,878,703 (“the ’703 patent”), all of which have been disclaimed…not infringe any claims of U.S. Patent No. 6,878,703 (“the ’703 patent”), all of which have been disclaimed | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
